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Abstract: Background:  To investigate the impact of combined degenerative mitral valve (DMV)
and coronary artery bypass grafting surgery (CABG+DMV) versus DMV surgery only
on in-hospital health outcome and 10-year survival.
Methods:  745 patients with DMV disease were identified. Of these, 186 (24.9%) were
affected also by coronary disease receiving combined DMV+CABG. They were
compared with the remaining 559 patients receiving DMV only surgery in terms of in-
hospital, 1, 5, and 10-year survival. We evaluated a short-term composite outcome of
hospital mortality, acute kidney injury, cerebro-vascular events and low cardiac output
requiring postoperative use of intra-aortic balloon pump. In addition, we assessed
mitral valve  repair rates over time and their correlation with long-term survival. To
minimise bias, we conducted a propensity score matching. 
Results:  DMV+CABG surgery was associated with a similar incidence of composite
endpoint compared to DMV surgery alone (6.5 vs 5.4 %, p=0.71 in the unmatched
analysis and 7.5% vs 8.2%, p=0.82 in the matched analysis). 10-year survival was 70.5
vs 68.6 % (p=0.07) for the unmatched analysis and 64.6 vs 62.5 % (p=0.9) for the
matched analysis, DMV+CABG vs DMV only respectively. Mitral valve repair had a
beneficial effect on short term outcomes and long-term mortality rates, regardless the
presence of concomitant coronary surgery.
Conclusions  : Combined DMV+CABG surgery is a very effective surgical treatment
with high mitral valve  repair rate.  Early in-hospital outcome and long-term survival are
comparable with DMV only surgery. In these combined procedures mitral valve repair
is associated with better long-term survival.
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Background: To investigate the impact of combined degenerative mitral valve (DMV) and coronary 
artery bypass grafting surgery (CABG+DMV) versus DMV surgery only on in-hospital health outcome 
and 10-year survival.  
Methods: 745 patients with DMV disease were identified. Of these, 186 (24.9%) were affected also 
by coronary disease receiving combined DMV+CABG. They were compared with the remaining 559 
patients receiving DMV only surgery in terms of in-hospital, 1, 5, and 10-year survival. We evaluated 
a short-term composite outcome of hospital mortality, acute kidney injury, cerebro-vascular events 
and low cardiac output requiring postoperative use of intra-aortic balloon pump. In addition, we 
assessed mitral valve  repair rates over time and their correlation with long-term survival. To 
minimise bias, we conducted a propensity score matching.   
Results: DMV+CABG surgery was associated with a similar incidence of composite endpoint 
compared to DMV surgery alone (6.5 vs 5.4 %, p=0.71 in the unmatched analysis and 7.5% vs 8.2%, 
p=0.82 in the matched analysis). 10-year survival was 70.5 vs 68.6 % (p=0.07) for the unmatched 
analysis and 64.6 vs 62.5 % (p=0.9) for the matched analysis, DMV+CABG vs DMV only 
respectively. Mitral valve repair had a beneficial effect on short term outcomes and long-term 
mortality rates, regardless the presence of concomitant coronary surgery.  
Conclusions: Combined DMV+CABG surgery is a very effective surgical treatment with high mitral 
valve repair rate. Early in-hospital outcome and long-term survival are comparable with DMV only 
surgery. In these combined procedures mitral valve repair is associated with better long-term survival.  
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Combined coronary artery bypass grafting (CABG) and valve surgery is generally considered a 
predictor of mortality, complications and reduced long-term survival [1]. Data from the UK and USA 
registries suggest that combined mitral valve (MV) and coronary surgery is associated with a 3 to 5 
folds increase of post-operative mortality compared to isolated MV procedures [1,2]. The UK registry 
suggests that in 2015 the 30-day mortality rate for combined MV and coronary surgery was 5.16% 
versus 2.83% for isolated MV surgery [2] and a recent report from >1200 US MEDICARE Hospitals 
suggests that combined MV and CABG surgery is associated with hospital mortality of >10% and 
reduced long-term survival rates [1]. However, this report generalises across the whole MV surgery 
spectrum, with no distinction across the different types of MV disease. Patients with ischemic mitral 
valve (IMV) disease undergoing combined IMV+CABG surgery are genuinely at high risk of in-
hospital mortality and reduced long-term survival [3]. Conversely, surgery for isolated degenerative 
mitral valve (DMV) disease is associated with lower mortality rate and superior long-term survival 
rates, especially when reparative techniques are used in high-volume centres [1,4,5]. Only few studies 
have investigated the impact of combined DMV and CABG surgery (DMV+CABG) on health 
outcomes [6]. Hence, outcome data associated with combined DMV+CABG are either still missing or 
poorly understood. Key examples of missing data include actual rates of in-hospital mortality and 
complications, long-term survival, reliability of logistic Euroscore in predicting mortality and impact 
of combined DMV+CABG on MV repair rates [7]. The aim of this study was to investigate the impact 
of the specific combination of degenerative mitral valve plus coronary (DMV+CABG) surgery versus 
DMV alone on 30-day mortality, hospital complication rates, MV repair rates, and on 1, 5, and 10-year 
survival and reoperation rates.  In addition, we evaluated the impact of the MV repair on the risk of 
early and long-term mortality in combined procedures compared to isolated DMV.  
 
Patients and Methods 
The key rationale for designing this study was to test the null hypothesis that CABG would not 
increase operative risks when specifically combined with degenerative MV disease. To this end we 




database validated and stored by an independent team, as part of the UK National Registry for Cardiac 
Surgery. The study protocol followed the local Institutional Clinical Audit Review Board and patient 
consent was waived. 
 
Patient selection 
Patient selection is shown in Figure 1. From January 2000 to March 2015 a total of 1,742 patients 
underwent any procedures involving mitral valve surgery at our institution (for more details see 
Supplemental table 1 and 2 and Supplemental file  Patient Selection).  A propensity matched analysis 
was conducted to minimize the impact of preoperative differences: after matching, 134 patients for each 
group were compared. 
 
Data collection and clinical management  
Baseline data included clinical characteristics, symptom status and past medical history of the patients. 
Logistic Euroscore was calculated according to established method [8]. Diagnosis of severe DMV and 
coronary disease was based on clinical history, preoperative echocardiograms and baseline coronary 
angiography. Elective patients were defined as those admitted from home, whereas urgent patients were 
those admitted from another hospital and requiring surgery within 7-10 day before discharge. Left 
ventricular ejection fraction (LVEF) was derived from baseline echocardiogram and classified as 
reduced if less than 50%. The surgical technique and postoperative care used was in keeping with 
surgeon’s preference (for more details see Supplemental file – Surgical Technique and Outcomes). 
Intraoperative and postoperative data collection and clinical management was as previously reported 
[9,10].  Late survival data after discharge were obtained from the UK National Health Service (NHS) 
tracing service with the latest data obtained in June 2015. 
 
Outcome Measures and definitions  
We used a composite outcome of in-hospital mortality, acute kidney injury (AKI), cerebro-vascular 




including reopening for bleeding, duration of hospital stays,1, 5 and 10-year survival as well as 5- and 
10-years MV reoperation rates. In-hospital mortality was defined as a death by any cause occurred at 
any time before discharge regardless the length of hospital stays. CVA consisted of any new post-
operative stroke identified clinically and/or by Computed Tomography (CT) scan. Occurrence of acute 
kidney injury was defined as need for postoperative hemofiltration/dialysis. Severe LCO was defined 
as the need to insert intra-operatively or postoperatively an intra-aortic balloon pump (IABP). Overtime, 
the rate of MV repair in both groups was assessed across consecutive 5-yer time periods. 
 
Statistical analysis  
Data are presented as mean ± one standard deviation for numerical variables that were normally 
distributed and as median and interquartile range (IQR) for the numerical variables not normally 
distributed. Categorical variables are shown as count and percentages. Comparison between numerical 
variables has been conducted using unpaired Student t-test if normally distributed and Mann-Whitney 
U test if not normally distributed. Categorical variables have been compared using Pearson Chi-square 
test or Fisher exact test as appropriate. A multiple logistic regression model has been used to identify 
predictors of in-hospital mortality: the final model was obtained with a stepwise approach.  Survival 
analysis was conducted comparing the survival functions of the two groups using Log-Rank test and 
Kaplan Meier Curves. In addition, a propensity score matching analysis was conducted to account for 
differences in baseline characteristics between groups. The matching process included the following 
variables: gender, New York Heart Association (NYHA) class, Canadian Cardiovascular Society (CCS) 
class, diabetes, hypertension, smoking history, peripheral vascular disease, logistic Euroscore, use of 
baseline inotropes, previous percutaneous coronary intervention (PCI), previous myocardial infarction 
(MI), reduced LVEF (<50%), nonelective surgery and re-operation. The nearest neighbour method was 
used, and the balance checked with standardised mean differences (SMD). After propensity score 
matching, variables were compared using paired Student t-test or paired Wilcoxon test for continuous 
variables and McNemar (for dichotomous variables) and Chi-square test for ordinal categorical 




evaluate the predictors of the in-hospital mortality. Patients were also divided by time-period of 
observation to allow a descriptive sub-analysis of changes in MV repair rate and key early health 
outcome overtime. All tests were two-sided with the alpha level set at 0.05 for statistical significance. 
Missing values were addressed with simple imputation methods. The statistical analysis was computed 
using R version 3.0.2 (R Core Team. R Foundation for Statistical Computing, Vienna, Austria).  
 
Results 
Preoperative characteristics of the patients before and after propensity score matching are shown in 
Table 1. 
 
Unmatched analysis   
The mean age of the overall population was 67.6 ± 11.8 years and logistic Euroscore was significantly 
higher in the DMV+CABG group (median 6 (IQR= 5-8) vs 5 (IQR = 3-7), p < 0.01).  
Intra-operative characteristics and post-operative outcomes of unmatched analysis are shown in Table 
2. As expected, cardiopulmonary bypass (CPB) time and aortic cross clamp times were longer in the 
DMV+CABG group. The predefined composite outcome did not differ between groups (6.5 % vs 5.4%, 
p=0.71). In-hospital mortality rate was 5.9% vs 3.8% (p = 0.29); CVA was 0% vs 1.3 % (p=0.27); AKI 
was 1.6% vs 0.9% (p = 0.68), while the occurrence of LCO was 0.0% in both groups, all DMV+CABG 
group vs DMV only group respectively. Reopening for bleeding was 6.9% vs 4.5% (p=0.71). Length 
of hospital stay was longer in this DMV+CABG vs DMV only group (median 9.5 vs 8 days (p = 0.04). 
The univariable logistic regression model did not identify DMV+CABG as an independent predictor of 
the composite (OR 1.61, 95% CI 0.73-3.34, p = 0.21) or of in-hospital mortality (OR 1.61, 95% CI 
0.73-3.34, p = 0.21). The adjusted multiple logistic regression model confirmed that DMV+CABG is 
neither a predictor of the predefined composite endpoint nor of in-hospital mortality. This model 
identified 3 predictors of in-hospital mortality including the use of MV replacement (OR 2.52, 95% CI 




time (OR 1.01, 95% CI 1.002-1.02, p = 0.01).  Long term survival rates for the unmatched analysis 
were similar between the two groups (Figure 2-A): DMV+ CABG patients had a survival rate of 94.4% 
at 1 year, 77.5% at 5-year and 63% at 10 years vs 93.2% at 1 year, 85.3% at 5 years and 70.6% at 10 
years for the DMV only group (p = 0.18). DMV+CABG did not affect the survival rates when assessed 
by a Cox proportional Hazard model (HR 1.58, 95% CI 0.87-2.04, p = 0.18).   
 
Matched analysis 
After propensity score matching (Table 1) the surgical operative times were found to be longer in the 
DMV+CABG with a median CPB time of 127 minutes vs 114 minutes in the DMV only group (p = 
0.02) and a median aortic cross-clamp time of 85 vs 80 minutes respectively (p = 0.16). The MV repair 
rates were 59.7% vs 68.9%, p=0.2. in the DMV+CABG vs DMV alone groups respectively. The 
predefined composite outcome did not differ between groups (7.5 % vs 8.2%, p=0.82). In-hospital 
mortality was 6.7% in the DMV+CABG vs 4.5% for the DMV only group (p=0.44), while post-
operative CVA was 0% vs 2.2 (p = 0.65), post-operative dialysis was 1.5 vs 2.2% (p = 0.65), and LCO 
was 0.0% in both groups, respectively. Length of hospital stay was also similar between the groups: 
median 9 (IQR 7-12.8) vs median 9(IQR 7-13.8) respectively (p = 0.35). The survival rates were 88 % 
at 1 year, 74.5 % at 5 years and 64.6% at 10 years for the DMV+CABG group and 89.2% at 1 year, 
73.9% at 5 years and 62.5% at 10 years for the DMV only group(p=0.9) (Figure 2-B). No independent 
predictors of mortality were found. 
 
Rates of mitral valve repair overtime and impact on short- and long-term outcome 
The overall MV repair rates were 62.9% vs 70.7%, (p=0.06) in the DMV+CABG vs DMV alone groups 
respectively. Differences in MV repair and health outcome by time-period are shown in Table 3 and 
Figure 3. The period between year 2000 and 2004 was characterised by a low rate of MV repair in our 
centre. However, this increased significantly after year 2004 with a peak of MV repair rate of 88.5% in 




rate was lower in the period between 2005-2009, while the lowest rate of composite health outcome 
was found in the final part of the series in concomitance with the highest repair rate. Higher rates of 
MV repair were also associated with higher long-term survival with an HR of 0.46 (95% CI 0.35-0.66). 
When adjusted for combined procedure (CABG) and cross-clamp time the beneficial effect of the MV 
repair on long-term survival was still confirmed (HR 0.47, 95% CI 0.33-0.68), showing that the 
complexity and the length of the surgery has no impact on the intrinsic beneficial effect of the repair 
procedure. During the follow up time, fifteen patients (2.01%) underwent a reoperation. Of these, 12 
procedures (1.63%) consisted of re-operations involving the mitral valve including 10 isolated MV 
reoperations and 2 procedures combined with aortic valve replacement. Of note, freedom from MV 




The combination of CABG and valve procedures has been generally associated with worst outcome 
after cardiac surgery [1,11-13]. Combined MV and CABG surgery has been largely investigated in the 
context of ischaemic mitral valve disease [14,15] with the results of this MV specific disease often 
uncritically generalised across the non-ischemic mitral disease spectrum[1], affecting the informed 
consenting of patients and the decision-making process toward percutaneous and/or medical treatment 
alternatives [16-18]. Yet, little is known on the outcome of DMV+CABG surgery [6,19].  
Our study shows that combined DMV+CABG has a similar rate of mortality, hospital complications, 
MV repairs, and long-term survival compared to DMV surgery alone. These findings highlight that 
patients afflicted by combined severe DMV and coronary disease should be offered combined 
DMV+CABG surgery instead of alternative and less validated alternatives.  
In this study, DMV+CABG surgery was not associated with worse outcome compared with DMV 
surgery alone for any of the health outcome measured. The only consistent difference observed was the 




evaluated showed similar results compared to DMV only group. A recent large report from US [1] 
found CABG to be an independent predictor of both short and long-term mortality, while this was not 
the case in our study.  However, the study population of the US report [1] was on average 5 years older 
compared to our patient cohort and encompassed a variety of valve pathologies and surgical procedures. 
Hence, a comparative evaluation is not appropriate as the observed results could reflect differences in 
baseline risk profile, surgical and anaesthetic practice as well as a different period of observation. In 
addition, observed outcome in the two studies might also reflect differences in volume of MV surgery 
and MV repair rates between centres [1]. In this study the rates of MV repair was 68.7% with no 
differences between groups, despite is an historical series, with 25% of patients receiving non-isolated 
MV, 8.2% having redo surgery, median age being 70 years, and 25% of patients being urgent 
admissions. As expected, the rate of MV repair rose over time reaching 85-90% by 2008. Of note, MV 
repair was associated with better short-term outcome and long-term survival.  
Previous studies have suggested that Euroscore may underestimate the mortality risk for combined 
surgery: in a study published in 2004, Karthik and colleagues reported a mortality rate after CABG plus 
valve surgery of 8.7% compared to a predicted value (additive Euroscore) of 6.7% [20]. Similar results 
were reported in another study suggesting that the Euroscore underestimated the impact of combined 
procedures (O/E = 1.09, p < 0.001) [21].  
The findings of this study confirm that combined DMV+CABG surgery is associated with low in-
hospital risk and excellent long-term survival particularly when MV repair is used. This confirms that 
a surgical practice by MV repair expertise may improve patient benefit and use of hospital resources. 
In addition, these findings may help the decision-making process toward surgery, instead of less 
validated percutaneous techniques or medical treatment alone. Recent evidence from meta-analysis and 
randomised trial suggest that the mitral clip procedure is associated with a very high rate of on table 
residual 2+ mitral regurgitation (MR), 7.3% of mortality at 1 year, and a freedom from combined death, 
repeat surgery, or grade 3+ or 4+ recurrent MR of only 39.8% at 4 years. These reports also highlight a 
need for open reoperation rates at 4 year of 25% in patients undergoing primary mitral clip treatment 




at high risk. Instead they should be referred for conventional surgery to high-volume MV repair surgery 
centres for consideration.  
The logistic regression model analysis did not identify DMV+CABG surgery as an independent 
predictor of mortality, while it confirmed that replacing the MV instead of repairing it is associated with 
worse health outcome. Others have already underlined this concept by showing that MV repair is the 
preferred option in these patients [7] with a reduced incidence of complications and mortality rate [24]. 
 There are limitations to this study: it is a retrospective analysis and no data is presented on long-term 
cardiac related events including recurrence of MR and quality of life/symptoms. In addition, a relatively 
small number of patients was under observation at 10-year follow-up. However, our series with 100% 
follow-up survival data, low rate of early composite endpoint and very good long-term survival is still 
a valuable and real reflection of clinical efficacy and patient well-being.  In addition, very few patients 
in the DMV only group (n=24) had mild or moderate coronary disease for which the Heart Team did 
not indicate the need for combined CABG surgery. Another possible limitation is related to the risk of 
Type II error and therefore the risk of non-rejection of a false null hypothesis as concomitant CABG is 
a recognised risk factor in valve surgery, hence larger studies are required to confirm our findings.  
In conclusion this study suggests that combined DMV+CABG surgery is safe and effective with a 30-
day mortality, complication rates, MV repair rates, and 1, 5, and 10-year survival comparable to DMV 
surgery only. It also indicates that MV repair should be the first choice in these combined cases of 
degenerative mitral valve and coronary disease due superior short-term health outcome and long-term 
survival beneficial effects.  These findings, if confirmed by larger studies, have important clinical 
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Figure 1. Flow diagram showing patient selection. 
Figure 2. Kaplan Meier curves showing survival rates for the two groups in the unmatched analysis 
(A) and in the propensity score matched analysis (B). 







Table 1. Preoperative characteristics before and after propensity score matching   
 
 Unmatched Analysis   Matched Analysis  
 DMV only DMV+CABG SMD p- value  DMV only DMV+CABG SMD p-value 
 559 186    134 134   
Age, years (median (IQR)) 69.8 (61-75.9) 70.2 (64-76.1) 0.162 0.07  71.5 (65-77.8) 69.9 (64.2- 76) 0.09 0.99 
Female gender (%) 185 (33.1) 36 (19.4) 0.316 <0.01  27 (20.1) 27(20.1) <0.01 1 
NYHA class > 3 (%) 272 (48.7) 91 (48.9) 0.005 1  66 (49.3) 62 (46.3) 0.06 0.68 
CCS Class > 3 (%) 9 (1.6) 32 (17.2) 0.554 <0.01  8 (6) 12 (9) 0.11 0.45 
Diabetes (%) 25 (4.5) 19 (10.2) 0.222 <0.01  8 (6) 10 (7.5) 0.06 0.80 
Hypertension (%) 242 (43.3) 107 (57.5) 0.288 <0.01  72 (53.7) 70 (52.2) 0.03 0.89 
Active Smoker (%) 21 (3.8) 8 (4.3) 0.028 0.91  7 (5.2) 4 (3) 0.10 0.43 
COPD (%) 55 (9.8) 18 (9.7) 0.005 1  17 (12.7) 13 (9.7) 0.09 0.56 
Previous CVA (%) 34 (6.1) 19 (10.2) 0.151 0.09  11 (8.2) 15 (11.2) 0.10 0.50 
PVD (%) 20 (3.6) 17 (9.1) 0.229 <0.01  7 (5.2) 6 (4.5) 0.03 1 
Logistic Euroscore (median(IQR)) 5 (3-7) 6 (5-8) 0.466 <0.01  6 (5-8) 6(5-8) 0.07 0.24 
Urgent surgery (%) 87 (15.6) 67 (36.0) 2.891 <0.01  31 (23.1) 35 (26.1) 0.07 0.64 
Redo-surgery 54(9.7) 7(3.8) 0.237 <0.01  8(6) 7(5.2) 0.03 1 
Previous MI (%) 24 (4.3) 48 (25.8) 0.631 <0.01  15 (11.2) 19 (14.2) 0.09 0.54 
Previous PCI (%) 11 (2.0) 12 (6.5) 0.225 <0.01  9(6.7) 5(3.7) 0.13 0.42 
MV Replacement (%) 164 (29.3) 69 (37.1) 0.165 0.06  43 (32.1) 54 (40.3) 0.17 0.25 
Reduced LVEF (%) 113 (20.2) 80 (43.0) 0.506 <0.01  45 (33.6) 47 (35.1) 0.03 0.87 
Number of CABG           




        1 graft 0(0) 78(41.9)  
 
 0(0) 69(51.5)   
        2 grafts 0(0) 63(21.5)  
 
 0(0) 41(30.6)   
        3 grafts 0(0) 37(19.9)  
 
 0(0) 20(14.9)   
        4 grafts 0(0) 8(4.3)  
 
 0(0) 4(3)   
    
 
     
  
 
Definitions: NYHA: New York Heart Association, CCS: Canadian Cardiovascular Surgery, COPD: Chronic Obstructive 
Pulmonary Disease, CVA: cerebro-vascular accident, PVD: peripheral vascular disease, MI: myocardial infarction, PCI: 













Table 2. Post-operative Outcomes before and after matching     
  Unmatched Analysis†   Matched Analysis‡ 
  DMV only DMV+CABG p-value   DMV only DMV + CABG p-value 
 559 186   134 134  
CPB Time, min (median(IQR)) 112 (91.5-135) 128 (110-160) <0.01  114(89-131.8) 127 (110-155) 0.02 
CA Time, min (median(IQR)) 80 (65-98) 84.5 (73.25-102) 0.01  80 (64-98) 85 (74-98.8) 0.16 
In Hospital Mortality 21 (3.8) 11 (5.9) 0.29  6 (4.5) 9 (6.7) 0.44 
Post-operative CVA 7 (1.3) 0 (0.0) 0.27  3 (2.2) 0 (0.0) 0.09 
Post-operative dialysis 5 (0.9) 3 (1.6) 0.68  3 (2.2) 2 (1.5) 0.65 
Re-sternotomy for bleeding 25(4.5) 13(6.9) 0.24  6(4.5) 7(5.2) 0.76 
Use of IABP  0(0) 0(0) NA  0(0) 0(0) NA 
Composite outcome 30(5.4) 12(6.5) 0.71  11(8.2) 10(7.5) 0.82 
Length of hospital Stay, days 
(median (IQR)) 8(6-11) 9.5 (7-14) <0.01   9(7-12.8) 9 (7-13.8) 0.35 
Definitions: CPB: Cardio-Pulmonary Bypass time, CA: Cardioplegic Arrest, CVA: cerebrovascular accidents, IABP: intra-aortic balloon pump. 
†: Unpaired Mann-Whitney test for numerical variables, Chi-squared or Fisher-exact test for categorical variables 


















 85  118  374  
       
MV Repair  20(23.5%)  118(65.9%)  374(77.8%) <0.01 
In Hospital Mortality 6(7.1%)  5(2.8%)  21(4.4%) 0.277 
Post-operative CVA 2(2.4%)  4(2.2%)  1(0.2%) 0.02 
Post-operative dialysis 2(2.4%)  4(2.2%)  2(0.4%) 0.06 
Composite outcome 8(9.4%)  12(6.7%)  22(4.6%) 0.159 




9(6-12)  8(6-12) 
0.676 
       
Definitions: MV: Mitral Valve; CVA: cerebrovascular accident; IQR: interquartile range.   
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Background: To investigate the impact of combined degenerative mitral valve (DMV) and coronary 
artery bypass grafting (CABG) surgery (CABG+DMV) versus DMV surgery only on in-hospital health 
outcome and 10-year survival.  
Methods: 745 patients with DMV disease were identified. Of these, 186 (24.9%) were affected also 
by coronary disease receiving combined DMV+CABG. They were compared with the remaining 559 
patients receiving DMV only surgery in terms of in-hospital, 1, 5, and 10-year survival. We evaluated 
a short-term composite outcome of hospital mortality, acute kidney injury,  cerebroinjury, cerebro-
vascular events and severe low cardiac output requiring postoperative use of intra-aortic balloon 
pump. In addition, we assessed mitral valve MV repair rates over time and their correlation with long-
term survival. To minimise bias, we conducted a propensity score matching.   
Results: DMV+CABG surgery was associated with a similar incidence of composite endpoint 
compared to DMV surgery alone (6.5 vs 5.4 %, p=0.71 in the unmatched analysis and 7.5% vs 8.2%, 
p=0.82 in the matched analysis). 10-year survival was 70.5 vs 68.6 % (p=0.07) for the unmatched 
analysis and 64.6 vs 62.5 % (p=0.9) for the matched analysis, DMV+CABG vs DMV only 
respectively. Mitral valveMV repair had a beneficial effect on short term outcomes and long-term 
mortality rates, regardless the presence of concomitant coronary surgery CABG.  
Conclusions: Combined DMV+CABG surgery is a very effective surgical treatment with high mitral 
valve  MV repair rate. Early in-hospital outcome and long-term survival are comparable with that of 
patients undergoing DMV only surgery. In these combined procedures mitral valveMV repair is 
associated with better long-term survival.  








List of abbreviations 
AKI: Acute Kidney Injury 
CABG: Coronary artery bypass grafting 
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Combined coronary artery bypass grafting (CABG) and valve surgery is generally considered a 
predictor of mortality, complications and reduced long-term survival [1]. Data from the UK and USA 
registries suggest that combined mitral valve (MV) and coronary surgery is associated with a 3 to 5 
folds increase of post-operative mortality compared to isolated MV procedures [1,2]. The UK registry 
suggests that in 2015 the 30-day mortality rate for combined MV and coronary surgery was 5.16% 
versus 2.83% for isolated MV surgery [2] and a recent report from >1200 US MEDICARE Hospitals 
suggests that combined MV and CABG surgery is associated with hospital mortality of >10% and 
reduced long-term survival rates [1]. However, this report generalises across the whole MV surgery 
spectrum, with no distinction across the different types of MV disease. Patients with ischemic mitral 
valve (IMV) disease undergoing combined IMV+CABG surgery are genuinely at high risk of in-
hospital mortality and reduced long-term survival [3]. Conversely, surgery for isolated degenerative 
mitral valve (DMV) disease is associated with lower mortality rate and superior long-term survival 
rates, especially when reparative techniques are used in high-volume centres [1,4,5]. Only few studies 
have investigated the impact of combined DMV and CABG surgery (DMV+CABG) on health 
outcomes [6]. Hence, outcome data associated with combined DMV+CABG are either still missing or 
poorly understood. Key examples of missing data include actual rates of in-hospital mortality and 
complications, long-term survival, reliability of logistic Euroscore in predicting mortality and impact 
of combined DMV+CABG on MV repair rates [7]. The aim of this study was to investigate the impact 
of the specific combination of degenerative mitral valve plus coronary (DMV+CABG) surgery versus 
DMV alone on 30-day mortality, hospital complication rates, MV repair rates, and on 1, 5, and 10-year 
survival and reoperation rates.  In addition, we evaluated the impact of the MV repair on the risk of 
early and long-term mortality in combined procedures compared to isolated DMV.  
 
Patients and Methods 
The key rationale for designing this study was to test the null hypothesis that CABG would not 




elected to undertake a retrospective analysis of prospectively collected data derived from our internal 
database validated and stored by an independent team, as part of the UK National Registry for Cardiac 
Surgery. The study protocol followed the local Institutional Clinical Audit Review Board and patient 
consent was waived. 
Patient selection 
Patient selection is shown in Figure 1. From January 2000 to March 2015 a total of 1,742 patients 
underwent any procedures involving mitral valve surgery at our institution (for more details see 
Supplemental table 1 and 2 and Supplemental file  Patient Selection).  A propensity matched analysis 
was conducted to minimize the impact of preoperative differences: after matching, 134 patients for each 
group were compared. 
Data collection and clinical management  
Baseline data included clinical characteristics, symptom status and past medical history of the patients. 
Logistic Euroscore was calculated according to established method [8]. Diagnosis of severe DMV and 
coronary disease was based on clinical history, preoperative echocardiograms and baseline coronary 
angiography. Elective patients were defined as those admitted from home, whereas urgent patients were 
those admitted from another hospital and requiring surgery within 7-10 day before discharge. Left 
ventricular ejection fraction (LVEF) was derived from baseline echocardiogram and classified as 
reduced if less than 50%. The surgical technique and postoperative care used was in keeping with 
surgeon’s preference (for more details see Supplemental file – Surgical Technique and Outcomes). 
Intraoperative and postoperative data collection and clinical management was as previously reported 
[9,10].  Late survival data after discharge were obtained from the UK National Health Service (NHS) 
tracing service with the latest data obtained in June 2015. 
Outcome Measures and definitions  
We used a composite outcome of in-hospital mortality, acute kidney injury (AKI), cerebro-vascular 
accidents (CVA) and severe low cardiac output (LCO). We also collected generic in-hospital outcome 
including reopening for bleeding, duration of hospital stays,1, 5 and 10-year survival as well as 5- and 




any time before discharge regardless the length of hospital stays. CVA consisted of any new post-
operative stroke identified clinically and/or by Computed Tomography (CT) scan. Occurrence of acute 
kidney injury was defined as need for postoperative hemofiltration/dialysis. Severe LCO was defined 
as the need to insert intra-operatively or postoperatively an intra-aortic balloon pump (IABP). Overtime, 
the rate of MV repair in both groups was assessed across consecutive 5-yer time periods. 
Statistical analysis  
Data are presented as mean ± one standard deviation for numerical variables that were normally 
distributed and as median and interquartile range (IQR) for the numerical variables not normally 
distributed. Categorical variables are shown as count and percentages. Comparison between numerical 
variables has been conducted using unpaired Student t-test if normally distributed and Mann-Whitney 
U test if not normally distributed. Categorical variables have been compared using Pearson Chi-square 
test or Fisher exact test as appropriate. A multiple logistic regression model has been used to identify 
predictors of in-hospital mortality: the final model was obtained with a stepwise approach.  Survival 
analysis was conducted comparing the survival functions of the two groups using Log-Rank test and 
Kaplan Meier Curves. In addition, a propensity score matching analysis was conducted to account for 
differences in baseline characteristics between groups. The matching process included the following 
variables: gender, New York Heart Association (NYHA) class, Canadian Cardiovascular Society (CCS) 
class, diabetes, hypertension, smoking history, peripheral vascular disease, logistic Euroscore, use of 
baseline inotropes, previous percutaneous coronary intervention (PCI), previous myocardial infarction 
(MI), reduced LVEF (<50%), nonelective surgery and re-operation. The nearest neighbour method was 
used, and the balance checked with standardised mean differences (SMD). After propensity score 
matching, variables were compared using paired Student t-test or paired Wilcoxon test for continuous 
variables and McNemar (for dichotomous variables) and Chi-square test for ordinal categorical 
variables and a conditional logistic regression model accounting for matching index was developed to 
evaluate the predictors of the in-hospital mortality. Patients were also divided by time-period of 
observation to allow a descriptive sub-analysis of changes in MV repair rate and key early health 




Missing values were addressed with simple imputation methods. The statistical analysis was computed 






Preoperative characteristics of the patients before and after propensity score matching are shown in 
Table 1. 
Unmatched analysis   
The mean age of the overall population was 67.6 ± 11.8 years and logistic Euroscore was significantly 
higher in the DMV+CABG group (median 6 (IQR= 5-8) vs 5 (IQR = 3-7), p < 0.01).  
Intra-operative characteristics and post-operative outcomes of unmatched analysis are shown in Table 
2. As expected, cardiopulmonary bypass (CPB) time and aortic cross clamp times were longer in the 
DMV+CABG group. The predefined composite outcome did not differ between groups (6.5 % vs 5.4%, 
p=0.71). In-hospital mortality rate was 5.9% vs 3.8% (p = 0.29); CVA was 0% vs 1.3 % (p=0.27); AKI 
was 1.6% vs 0.9% (p = 0.68), while the occurrence of LCO was 0.0% in both groups, all DMV+CABG 
group vs DMV only group respectively. Reopening for bleeding was 6.9% vs 4.5% (p=0.71). Length 
of hospital stay was longer in this DMV+CABG vs DMV only group (median 9.5 vs 8 days (p = 0.04). 
The univariable logistic regression model did not identify DMV+CABG as an independent predictor of 
the composite (OR 1.61, 95% CI 0.73-3.34, p = 0.21) or of in-hospital mortality (OR 1.61, 95% CI 
0.73-3.34, p = 0.21). The adjusted multiple logistic regression model confirmed that DMV+CABG is 
neither a predictor of the predefined composite endpoint nor of in-hospital mortality. This model 
identified 3 predictors of in-hospital mortality including the use of MV replacement (OR 2.52, 95% CI 
1.14-5.73, p =0.02), logistic Euroscore (OR 1.40, 95% CI 1.23 – 1.50, p < 0.01), and prolonged CPB 
time (OR 1.01, 95% CI 1.002-1.02, p = 0.01).  Long term survival rates for the unmatched analysis 




at 1 year, 77.5% at 5-year and 63% at 10 years vs 93.2% at 1 year, 85.3% at 5 years and 70.6% at 10 
years for the DMV only group (p = 0.18). DMV+CABG did not affect the survival rates when assessed 
by a Cox proportional Hazard model (HR 1.58, 95% CI 0.87-2.04, p = 0.18).   
 
Matched analysis 
After propensity score matching (Table 1) the surgical operative times were found to be longer in the 
DMV+CABG with a median CPB time of 127 minutes vs 114 minutes in the DMV only group (p = 
0.02) and a median aortic cross-clamp time of 85 vs 80 minutes respectively (p = 0.16). The MV repair 
rates were 59.7% vs 68.9%, p=0.2. in the DMV+CABG vs DMV alone groups respectively. The 
predefined composite outcome did not differ between groups (7.5 % vs 8.2%, p=0.82). In-hospital 
mortality was 6.7% in the DMV+CABG vs 4.5% for the DMV only group (p=0.44), while post-
operative CVA was 0% vs 2.2 (p = 0.65), post-operative dialysis was 1.5 vs 2.2% (p = 0.65), and LCO 
was 0.0% in both groups, respectively. Length of hospital stay was also similar between the groups: 
median 9 (IQR 7-12.8) vs median 9(IQR 7-13.8) respectively (p = 0.35). The survival rates were 88 % 
at 1 year, 74.5 % at 5 years and 64.6% at 10 years for the DMV+CABG group and 89.2% at 1 year, 
73.9% at 5 years and 62.5% at 10 years for the DMV only group(p=0.9) (Figure 2-B). No independent 
predictors of mortality were found. 
Rates of mitral valve repair overtime and impact on short- and long-term outcome 
The overall MV repair rates were 62.9% vs 70.7%, (p=0.06) in the DMV+CABG vs DMV alone groups 
respectively. Differences in MV repair and health outcome by time-period are shown in Table 3 and 
Figure 3. The period between year 2000 and 2004 was characterised by a low rate of MV repair in our 
centre. However, this increased significantly after year 2004 with a peak of MV repair rate of 88.5% in 
2009 (Figure 3). The main health outcomes at different time periods is shown in Table 3: mortality 
rate was lower in the period between 2005-2009, while the lowest rate of composite health outcome 
was found in the final part of the series in concomitance with the highest repair rate. Higher rates of 




When adjusted for combined procedure (CABG) and cross-clamp time the beneficial effect of the MV 
repair on long-term survival was still confirmed (HR 0.47, 95% CI 0.33-0.68), showing that the 
complexity and the length of the surgery has no impact on the intrinsic beneficial effect of the repair 
procedure. During the follow up time, fifteen patients (2.01%) underwent a reoperation. Of these, 12 
procedures (1.63%) consisted of re-operations involving the mitral valve including 10 isolated MV 
reoperations and 2 procedures combined with aortic valve replacement. Of note, freedom from MV 




The combination of CABG and valve procedures has been generally associated with worst outcome 
after cardiac surgery [1,11-13]. Combined MV and CABG surgery has been largely investigated in the 
context of ischaemic mitral valve disease [14,15] with the results of this MV specific disease often 
uncritically generalised across the non-ischemic mitral disease spectrum[1], affecting the informed 
consenting of patients and the decision-making process toward percutaneous and/or medical treatment 
alternatives [16-18]. Yet, little is known on the outcome of DMV+CABG surgery [6,19].  
Our study shows that combined DMV+CABG has a similar rate of mortality, hospital complications, 
MV repairs, and long-term survival compared to DMV surgery alone. These findings highlight that 
patients afflicted by combined severe DMV and coronary disease should be offered combined 
DMV+CABG surgery instead of alternative and less validated alternatives.  
In this study, DMV+CABG surgery was not associated with worse outcome compared with DMV 
surgery alone for any of the health outcome measured. The only consistent difference observed was the 
longer CPB time in the combined group.  Even in the unmatched analysis all the outcome measures 
evaluated showed similar results compared to DMV only group.  
Contrary to Aa recent large report from US [1] found CABG to be an independent predictor of both 




DMV+CABG surgery to be a predictor of in-hospital and long-term mortality; our early and late 
mortality rates were lower than those described in the US report.  However, the study population of the 
US report [1] was on average 5 years older compared to our patient cohort and encompassed a variety 
of valve pathologies and surgical procedures. Hence, a comparative evaluation is not appropriate as the 
observed results could reflect differences in baseline risk profile, surgical and anaesthetic practice as 
well as a different period of observation. In addition, observed outcome in the two studies might also 
reflect differences in volume of MV surgery and MV repair rates between centres [1]. In this study the 
rates of MV repair was 68.7% with no differences between groups, despite is an historical series, with 
25% of patients receiving non-isolated MV, 8.2% having redo surgery, median age being 70 years, and 
25% of patients being urgent admissions. As expected, the rate of MV repair rose over time reaching 
85-90% by 2008. Of note, MV repair was associated with better short-term outcome and long-term 
survival.  
Previous studies have suggested that Euroscore may underestimate the mortality risk for combined 
surgery: in a study published in 2004, Karthik and colleagues reported a mortality rate after CABG plus 
valve surgery of 8.7% compared to a predicted value (additive Euroscore) of 6.7% [20]. Similar results 
were reported in another study suggesting that the Euroscore underestimated the impact of combined 
procedures (O/E = 1.09, p < 0.001) [21].  
The findings of this study confirm that combined DMV+CABG surgery is associated with low in-
hospital risk and excellent long-term survival particularly when MV repair is used. This confirms that 
a surgical practice by MV repair expertise may improve patient benefit and use of hospital resources. 
In addition, these findings may help the decision-making process toward surgery, instead of less 
validated percutaneous techniques or medical treatment alone. Recent evidence from meta-analysis and 
randomised trial suggest that the mitral clip procedure is associated with a very high rate of on table 
residual 2+ mMitral regurgitation (MR), 7.3% of mortality at 1 year, and a freedom from combined 
death, repeat surgery, or grade 3+ or 4+ recurrent MR of only 39.8% at 4 years. These reports also 
highlight a need for open reoperation rates at 4 year of 25% in patients undergoing primary mitral clip 




regarded at high risk. Instead they should be referred for conventional surgery to high-volume MV 
repair surgery centres for consideration.  
The logistic regression model analysis did not identify DMV+CABG surgery as an independent 
predictor of mortality, while it confirmed that replacing the MV instead of repairing it is associated with 
worse health outcome. Others have already underlined this concept by showing that MV repair is the 
preferred option in these patients [7] with a reduced incidence of complications and mortality rate [24]. 
 There are limitations to this study: it is a retrospective analysis and no data is presented on long-term 
cardiac related events including recurrence of MR and quality of life/symptoms. In addition, a relatively 
small number of patients was under observation at 10-year follow-up. However, our series with 100% 
follow-up survival data, low rate of early composite endpoint and very good long-term survival is still 
a valuable and real reflection of clinical efficacy and patient well-being.  In addition, very few patients 
in the DMV only group (n=24) had mild or moderate coronary disease for which the Heart Team did 
not indicate the need for combined CABG surgery. Another possible limitation is related to the risk of 
Type II error and therefore the risk of non-rejection of a false null hypothesis as concomitant CABG is 
a recognised risk factor in valve surgery, hence larger studies are required to confirm our findings.  
In conclusion this study suggests that combined DMV+CABG surgery is safe and effective with a 30-
day mortality, complication rates, MV repair rates, and 1, 5, and 10-year survival comparable to DMV 
surgery only. It also indicates that MV repair should be the first choice in these combined cases of 
degenerative mitral valve and coronary disease due superior short-term health outcome and long-term 
survival beneficial effects.  These findings, if confirmed by larger studies, have important clinical 
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Figure 1. Flow diagram showing patient selection. 
 
 
Figure 2. Kaplan Meier curves showing survival rates for the two groups in the unmatched analysis (A) 
and in the propensity score matched analysis (B). 
 







Table 1. Preoperative characteristics before and after propensity score matching   
 
 Unmatched Analysis   Matched Analysis  
 DMV only DMV+CABG SMD p- value  DMV only DMV+CABG SMD p-value 
 559 186    134 134   
Age, years (median (IQR)) 69.8 (61-75.9) 70.2 (64-76.1) 0.162 0.07  71.5 (65-77.8) 69.9 (64.2- 76) 0.09 0.99 
Female gender (%) 185 (33.1) 36 (19.4) 0.316 <0.01  27 (20.1) 27(20.1) <0.01 1 
NYHA class > 3 (%) 272 (48.7) 91 (48.9) 0.005 1  66 (49.3) 62 (46.3) 0.06 0.68 
CCS Class > 3 (%) 9 (1.6) 32 (17.2) 0.554 <0.01  8 (6) 12 (9) 0.11 0.45 
Diabetes (%) 25 (4.5) 19 (10.2) 0.222 <0.01  8 (6) 10 (7.5) 0.06 0.80 
Hypertension (%) 242 (43.3) 107 (57.5) 0.288 <0.01  72 (53.7) 70 (52.2) 0.03 0.89 
Active Smoker (%) 21 (3.8) 8 (4.3) 0.028 0.91  7 (5.2) 4 (3) 0.10 0.43 
COPD (%) 55 (9.8) 18 (9.7) 0.005 1  17 (12.7) 13 (9.7) 0.09 0.56 
Previous CVA (%) 34 (6.1) 19 (10.2) 0.151 0.09  11 (8.2) 15 (11.2) 0.10 0.50 
PVD (%) 20 (3.6) 17 (9.1) 0.229 <0.01  7 (5.2) 6 (4.5) 0.03 1 
Logistic Euroscore (median(IQR)) 5 (3-7) 6 (5-8) 0.466 <0.01  6 (5-8) 6(5-8) 0.07 0.24 
Urgent surgery (%) 87 (15.6) 67 (36.0) 2.891 <0.01  31 (23.1) 35 (26.1) 0.07 0.64 
Redo-surgery 54(9.7) 7(3.8) 0.237 <0.01  8(6) 7(5.2) 0.03 1 
Previous MI (%) 24 (4.3) 48 (25.8) 0.631 <0.01  15 (11.2) 19 (14.2) 0.09 0.54 
Previous PCI (%) 11 (2.0) 12 (6.5) 0.225 <0.01  9(6.7) 5(3.7) 0.13 0.42 
MV Replacement (%) 164 (29.3) 69 (37.1) 0.165 0.06  43 (32.1) 54 (40.3) 0.17 0.25 
Reduced LVEF (%) 113 (20.2) 80 (43.0) 0.506 <0.01  45 (33.6) 47 (35.1) 0.03 0.87 
Number of CABG           




        1 graft 0(0) 78(41.9)  
 
 0(0) 69(51.5)   
        2 grafts 0(0) 63(21.5)  
 
 0(0) 41(30.6)   
        3 grafts 0(0) 37(19.9)  
 
 0(0) 20(14.9)   
        4 grafts 0(0) 8(4.3)  
 
 0(0) 4(3)   
    
 
     
 Definitions: NYHA: New York Heart Association, CCS: Canadian Cardiovascular Surgery, COPD: Chronic Obstructive 
Pulmonary Disease, CVA: cerebro-vascular accident, PVD: peripheral vascular disease, MI: myocardial infarction, PCI: 













Table 2. Post-operative Outcomes before and after matching     
  Unmatched Analysis†   Matched Analysis‡ 
  DMV only DMV+CABG p-value   DMV only DMV + CABG p-value 
 559 186   134 134  
CPB Time, min (median(IQR)) 112 (91.5-135) 128 (110-160) <0.01  114(89-131.8) 127 (110-155) 0.02 
CA Time, min (median(IQR)) 80 (65-98) 84.5 (73.25-102) 0.01  80 (64-98) 85 (74-98.8) 0.16 
In Hospital Mortality 21 (3.8) 11 (5.9) 0.29  6 (4.5) 9 (6.7) 0.44 
Post-operative CVA 7 (1.3) 0 (0.0) 0.27  3 (2.2) 0 (0.0) 0.09 
Post-operative dialysis 5 (0.9) 3 (1.6) 0.68  3 (2.2) 2 (1.5) 0.65 
Re-sternotomy for bleeding 25(4.5) 13(6.9) 0.24  6(4.5) 7(5.2) 0.76 
Use of IABP  0(0) 0(0) NA  0(0) 0(0) NA 
Composite outcome 30(5.4) 12(6.5) 0.71  11(8.2) 10(7.5) 0.82 
Length of hospital Stay, days 
(median (IQR)) 8(6-11) 9.5 (7-14) <0.01   9(7-12.8) 9 (7-13.8) 0.35 
Definitions: CPB: Cardio-Pulmonary Bypass time, CA: Cardioplegic Arrest, CVA: cerebrovascular accidents, IABP: intra-aortic balloon pump. 
†: Unpaired Mann-Whitney test for numerical variables, Chi-squared or Fisher-exact test for categorical variables 


















 85  118  374  
       
MV Repair  20(23.5%)  118(65.9%)  374(77.8%) <0.01 
In Hospital Mortality 6(7.1%)  5(2.8%)  21(4.4%) 0.277 
Post-operative CVA 2(2.4%)  4(2.2%)  1(0.2%) 0.02 
Post-operative dialysis 2(2.4%)  4(2.2%)  2(0.4%) 0.06 
Composite outcome 8(9.4%)  12(6.7%)  22(4.6%) 0.159 




9(6-12)  8(6-12) 
0.676 
       
Definitions: MV: Mitral Valve; CVA: cerebrovascular accident; IQR: interquartile range.   
 
